Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Conditions

• Metastatic Invasive Breast Cancer
• Resistant Breast Cancer
• ER+, HER2-, Metastatic Breast Cancer

Interventions

• DRUG: Neratinib + endocrine therapy
• DRUG: Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant
• DRUG: CDK4/6 + Endocrine therapy

Sponsor

University of California, San Diego